Psychedelic research gains momentum, as early trial suggests micro-dosing LSD is safe
Psychedelics have been long neglected as the subject of vigorous scientific research after governments branded them as illegal hedonistic compounds with no therapeutic potential. But in recent years, despite tricky regulations, a resurgence of interest from researchers has culminated in an FDA approved ketamine-derived depression treatment, clinical trials testing the potential of psilocybin in ‘magic mushrooms,’ and the setting up of a psychedelic research center at Johns Hopkins.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.